Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Citations Over TimeTop 1% of 2020 papers
Abstract
Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-recovered participants, developed neutralization assays to investigate antibody responses, adapted our high-throughput antibody generation pipeline to rapidly screen more than 1800 antibodies, and established an animal model to test protection. We isolated potent neutralizing antibodies (nAbs) to two epitopes on the receptor binding domain (RBD) and to distinct non-RBD epitopes on the spike (S) protein. As indicated by maintained weight and low lung viral titers in treated animals, the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs also define protective epitopes to guide vaccine design.
Related Papers
- → Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma(2021)54 cited
- → Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01(2019)10 cited
- → An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization Titer(1980)86 cited
- → Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals(2016)1 cited
- → Heterogeneity in the Properties of 7 S and 19 S Rabbit-Neutralizing Antibodies to Herpes Simplex Virus(1968)101 cited